Clinical trial
Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of…
NCT00056810 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00056810 |
|---|---|
| Title | Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine |
| Official title | Assessment of Chronic GBS Improvement With Use of 4-AP |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Guillain-Barre Syndrome |
| Intervention type | Drug |
| Interventions | 4-aminopyridine (4-AP) |
| Enrollment | 30 |
| Start date | Sep 1, 2002 |
| Completion | May 1, 2005 |
| First posted | Mar 25, 2003 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: